May 13th 2024
A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
mRNA COVID-19 Vaccines Safe Among Patients With Cancer History
February 7th 2022A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.
Read More
Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer
February 2nd 2022Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Read More
Persistent Care Variations Uncovered in New Breast Cancer Study
January 27th 2022This new analysis among patients with stage I to III breast cancer investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy initiation, and endocrine therapy continuation.
Read More
Dr Funmi Olopade Previews Her Keynote Address for SABCS
December 6th 2021Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, previews her keynote address for the San Antonio Breast Cancer Symposium (SABCS).
Watch
Dr Funmi Olopade on WISDOM: When You Ask Women to Participate, They Sign Up
October 20th 2021The WISDOM study—Women Informed to Screen Depending On Measures of risk—was launched to test a personalized approach to screening compared to annual mammograms. Funmi Olopade, MD, FACP, is a professor of Medicine and Human Genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, and a co-investigator of WISDOM. She is an expert on understanding the etiology and genomic basis of cancer progression in diverse populations and has published extensively on both genetic and non-genetic risk factors for breast cancer. She discussed overcoming early challenges of low enrollment of Black women in the study.
Watch
The Pfizer and Moderna COVID-19 vaccines were shown to be 90% effective in preventing infection in a real-world setting; Biden administration urges states to pause reopening plans amid signs of COVID-19 surge; a lawsuit seeks to end the requirement that preventive services be provided free of charge to Americans.
Read More
The FDA issues updated guidance on the emergency use authorization (EUA) process for COVID-19 screening tools; Eli Lilly releases patient-reported outcome results for Verzenio (abemaciclib) in breast cancer; COVID-19 vaccines possibly improve long-haul symptoms among patients.
Read More
As Mammography Screenings Drop, Advanced Breast Cancer Cases Increase in First Months of COVID-19
February 15th 2021The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
Read More
An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.
Read More
Dr Alexey Aleshin: Chemotherapy Is Meant to Eliminate, Reduce Disease Burden
January 1st 2021Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Watch
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Read More
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Read More
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Read More
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Read More
Dr Alexey Aleshin: I-SPY 2 Findings Show How We Can Dynamically Monitor ctDNA
December 18th 2020Patient plasma samples from this study show residual circulating tumor DNA (ctDNA) correlates with a poor prognosis in women with early-stage breast cancer, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Watch
Uptick in Early-Stage Breast Cancer Diagnoses Seen Among Minority Women Following ACA Implementation
December 14th 2020Compared with before the Affordable Care Act (ACA), study results show there was an increase in diagnoses of early-stage breast cancer among younger vs older minority women after the act.
Read More